Publication Name	World Journal of Clinical Cases
Manuscript ID	75345
Country	China

Received	2022-01-25 12:50
Peer-Review Started	2022-01-25 12:50
To Make the First Decision
Return for Revision	2022-03-16 01:37
Revised	2022-03-18 12:58
Second Decision	2022-04-01 02:14
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-04-03 22:28
Articles in Press	2022-04-03 22:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-05-11 12:33
Publish the Manuscript Online	2022-06-09 07:17

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Jing Yu and Nanlin Li
ORCID	Author(s) ORCID Number Jing Yu http://orcid.org/0000-0001-9733-9286 Nanlin Li http://orcid.org/0000-0002-7212-1026
Funding Agency and Grant Number
Corresponding Author	Nanlin Li, MD, Associate Chief Physician, Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Air Force Medical University, No. 127 West Changle Road, Xi’an 710032, Shaanxi Province, China. yuyujing0729@163.com
Key Words	Human epidermal receptor-2+ breast cancer; Human epidermal receptor-2 loss; Neoadjuvant treatment; Case report
Core Tip	We presented a case diagnosed with the human epidermal receptor(HER)-2+ breast cancer patient who exhibited changes in the expression of HER-2 receptors on tumour samples from surgical specimens obtained after neoadjuvant treatment (NAT) compared with initial biopsy. Changes in HER-2 expression after NAT should be retested by physicians and pathologists before systemic treatment instead of avoiding further HER-2-targeted therapy. In general, the exact mechanisms of HER-2 discordance remain unknown and further investigations are needed.
Publish Date	2022-06-09 07:17
Citation	Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928
URL	https://www.wjgnet.com/2307-8960/full/v10/i17/5923.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i17.5923

Full Article (PDF)	WJCC-10-5923.pdf
Full Article (Word)	WJCC-10-5923.docx
Manuscript File	75345_Auto_Edited.docx
Answering Reviewers	75345-Answering reviewers.pdf
Audio Core Tip	75345-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	75345-Conflict-of-interest statement.pdf
Copyright License Agreement	75345-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	75345-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	75345-Language certificate.pdf
Peer-review Report	75345-Peer-review(s).pdf
Scientific Misconduct Check	75345-Bing-Wang LL-2.png
Scientific Editor Work List	75345-Scientific editor work list.pdf
CrossCheck Report	75345-CrossCheck report.pdf